DCT

1:23-cv-00179

Novo Nordisk Inc v. Orbicular Pharmaceutical Tech Pvt Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:23-cv-00179, D. Del., 02/17/2023
  • Venue Allegations: Plaintiff alleges venue is proper based on Defendant's business activities in Delaware and its previous consent to personal jurisdiction in the district in a prior case.
  • Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to market a generic version of the diabetes drug Victoza® constitutes an act of infringement of two patents related to the drug's formulation and its injection device.
  • Technical Context: The patents-in-suit cover a stable pharmaceutical formulation for injectable peptide drugs and a mechanical push-button design for an injection pen, both relevant to the delivery of biologic medicines.
  • Key Procedural History: This action was initiated under the Hatch-Waxman Act following a notice letter from the Defendant, which included a Paragraph IV Certification asserting that the patents-in-suit are invalid, unenforceable, or will not be infringed by its proposed generic product. The complaint references prior litigation between the parties where the Defendant consented to jurisdiction in the District of Delaware.

Case Timeline

Date Event
2003-11-24 '833 Patent Priority Date
2007-02-07 '893 Patent Priority Date
2012-02-14 '833 Patent Issue Date
2016-02-23 '893 Patent Issue Date
2023-01-04 Defendant's Notice Letter to Plaintiff
2023-02-17 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,114,833 - "Propylene Glycol-Containing Peptide Formulations Which Are Optimal for Production and for Use in Injection Devices"

The Invention Explained

  • Problem Addressed: The patent's background section describes problems associated with using mannitol as an isotonicity agent in peptide formulations, noting that it can crystallize, leading to deposits on production equipment and clogging of injection devices '833 Patent, col. 1:30-45
  • The Patented Solution: The invention proposes using propylene glycol as an alternative isotonicity agent in peptide formulations '833 Patent, abstract This substitution is described as reducing deposits during the manufacturing process and minimizing the clogging of injection devices, resulting in a more physically and chemically stable product suitable for injection '833 Patent, col. 1:51-62
  • Technical Importance: The solution offered a way to improve manufacturing efficiency and the reliability of drug delivery devices for self-administered peptide therapeutics '833 Patent, col. 1:35-45

Key Claims at a Glance

  • The complaint asserts infringement of claims 1-31 of the '833 Patent Compl. ¶20 Independent claim 1 is representative of the composition claims.
  • Independent Claim 1 Elements:
    • A pharmaceutical formulation comprising at least one GLP-1 agonist,
    • a disodium phosphate dihydrate buffer and
    • propylene glycol,
    • wherein said propylene glycol is present in said formulation in a final concentration of from about 1 mg/ml to about 100 mg/ml and
    • wherein said formulation has a pH of from about 7.0 to about 10.0.
  • The complaint alleges that claims 16-31, directed to methods of preparation and use, would also be infringed Compl. ¶20

U.S. Patent No. 9,265,893 - "Injection Button"

The Invention Explained

  • Problem Addressed: In injection pens where a user pushes a non-rotating button to actuate a rotating internal drive mechanism, friction between the two components can increase the force required to administer an injection '893 Patent, col. 1:29-34
  • The Patented Solution: The invention is a push button connection that minimizes this friction by using a "pivot bearing" between the push button and the driving part '893 Patent, abstract '893 Patent, col. 2:51-57 This design reduces the surface area of interaction and the radius of the resulting friction force, thereby lowering the actuation force needed from the user '893 Patent, col. 2:51-57 The design also incorporates radial bearings to manage forces applied off-center on the button '893 Patent, col. 2:5-15
  • Technical Importance: This mechanical improvement is intended to make injection pens easier for patients to operate, particularly for those with limited hand strength '893 Patent, col. 2:42-45

Key Claims at a Glance

  • The complaint asserts infringement of claims 1-6 of the '893 Patent Compl. ¶26 Claim 1 is the sole independent claim.
  • Independent Claim 1 Elements:
    • A push button connection for an injection device comprising:
    • a push button mountable on a driving part being rotatable relatively to the push button and which push button further comprises a bore with a bottom surface and which bore surrounds a protrusion on the driving part
    • which protrusion has a top surface and wherein a pivot bearing is formed between the bottom surface and the top surface,
    • wherein when a user presses on the push button the force is directed toward the driving part and
    • wherein the driving part rotates relative to the push button.

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is "Orbicular's Product," identified as a generic version of liraglutide injection solution, 18 mg/3 ml (6 mg/ml), for which Orbicular submitted ANDA No. 217590 to the FDA Compl. ¶15

Functionality and Market Context

  • The complaint alleges that Orbicular's ANDA seeks approval to market its product as a generic version of Novo Nordisk's Victoza® Compl. ¶1 Compl. ¶15 The ANDA is said to refer to and rely upon the Victoza® New Drug Application and to contain data demonstrating bioequivalence between Orbicular's Product and Victoza® Compl. ¶16
  • The complaint does not provide specific technical details about the formulation composition or the mechanics of the injection device for Orbicular's Product.
    No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide sufficient detail for a claim-chart analysis. The infringement allegations are pleaded generally, stating that the manufacture, use, or sale of Orbicular's Product during the patent terms would infringe the asserted claims Compl. ¶20 Compl. ¶26

The infringement theory for the '833 Patent is that Orbicular's generic liraglutide product, as described in its ANDA, will meet the elements of the asserted formulation claims Compl. ¶20 Notably, the complaint alleges that in its Paragraph IV Certification, "Orbicular did not contest its infringement of any claims of the '833 patent, except to the extent that it contends that those claims are invalid" Compl. ¶20

The infringement theory for the '893 Patent is that the injection device that will be used to administer Orbicular's Product contains a "push button connection" that meets the structural and functional limitations of the asserted claims Compl. ¶26

  • Identified Points of Contention:
    • Factual Questions ('833 Patent): While the complaint suggests infringement of the '833 patent is not contested, a potential dispute would center on whether the formulation detailed in Orbicular's confidential ANDA contains propylene glycol within the claimed concentration range and has a pH within the claimed range.
    • Structural Questions ('893 Patent): A central question will be whether the specific mechanical interface between the push button and driving part of the accused injection device constitutes a "pivot bearing" as required by claim 1. This analysis will depend on the precise structure of the components in Orbicular's device.
    • Validity vs. Infringement: The complaint's assertion that Orbicular does not contest infringement of the '833 patent suggests that the primary dispute for that patent may concern validity rather than infringement Compl. ¶20

V. Key Claim Terms for Construction

  • '833 Patent, Claim 1

    • The Term: "about"
    • Context and Importance: The term "about" modifies the numerical ranges for both the propylene glycol concentration ("about 1 mg/ml to about 100 mg/ml") and the pH ("about 7.0 to about 10.0"). The construction of this term is critical for determining the scope of the claims and whether Orbicular's formulation, which may be formulated near the boundaries of these ranges, literally infringes.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The specification uses the term "about" when describing various concentration and pH ranges, suggesting the inventors did not intend for the recited values to be absolute endpoints '833 Patent, col. 10:14-31
      • Evidence for a Narrower Interpretation: A party might argue that the specific numerical values used in the patent's examples, such as "13.7 or 35.9 mg/ml" for propylene glycol, provide context that limits the scope of "about" to a degree of precision consistent with those examples '833 Patent, col. 19:15

  • '893 Patent, Claim 1

    • The Term: "pivot bearing"
    • Context and Importance: This term is the central structural element of the claimed invention, intended to reduce friction. Its definition will determine what types of mechanical interfaces between the push button and the driving part fall within the scope of the claim.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The specification describes the function of the pivot bearing as minimizing "the surface area of interaction" and "the radius of the resulting friction force" '893 Patent, col. 2:53-57 This functional language may support a construction that covers any structure achieving this result.
      • Evidence for a Narrower Interpretation: The preferred embodiment discloses a specific structure where a "raised pointer forming a pivot 18" on the push button contacts the "top surface 22" of the protrusion on the driving part '893 Patent, col. 3:63-65 '893 Patent, Fig. 1 This could support a narrower construction limited to a point-contact or convex-on-flat configuration.

VI. Other Allegations

  • Indirect Infringement: The complaint is brought under 35 U.S.C. § 271(e)(2)(A), which defines the submission of an ANDA seeking approval to market a generic drug prior to patent expiration as a statutory act of infringement Compl. ¶19 Compl. ¶25 This framework addresses the future, intended infringement that would occur upon FDA approval and commercialization.
  • Willful Infringement: The complaint alleges that Orbicular "was aware of" the '833 and '893 patents when it submitted its ANDA Compl. ¶23 Compl. ¶29 This allegation of pre-suit knowledge, coupled with the request for a finding that the case is "exceptional" under 35 U.S.C. § 285, lays the groundwork for a claim of willful infringement Compl. Prayer F

VII. Analyst's Conclusion: Key Questions for the Case

  • A primary issue appears to be one of validity versus infringement. For the '833 formulation patent, the complaint suggests infringement is not in dispute, which would shift the case's focus to whether Orbicular can prove the asserted claims are invalid. For the '893 device patent, the dispute will likely involve both infringement and validity.
  • A key technical question will be one of structural correspondence: Does the injection device described in Orbicular's confidential ANDA incorporate a mechanical interface that meets the specific limitations of a "pivot bearing" as that term will be construed by the court?
  • The overarching question is inherent to all ANDA litigation: Does the product that Orbicular seeks to market-both its chemical formulation and its delivery device-fall within the scope of a valid and enforceable claim of the patents-in-suit?
Loading Complaint